Caster Semenya of South Africa celebrates after winning the womens 800m final at the Rio 2016 Olympic Games. Photograph: Diego Azubel/EPA Caster Semenya, the Olympic 800m champion, may be banned from competing at future Games unless she undergoes hormone replacement therapy (HRT) or even surgery in the wake of a landmark study into athletes with raised testosterone levels which has just been published. The International Association of Athletics Federations, the world governing body, commissioned research which has produced the most conclusive evidence yet that female athletes with very high levels of naturally occurring testosterone receive significant performance-enhancing benefits in competition. It comes only weeks before the IAAF is set to challenge a ruling by the court of arbitration for sport which, since 2015, has prevented it from restricting permitted levels of testosterone among female competitors. The new study will not stop Semenya and other hyperandrogenic athletes, such as the Indian sprinter Dutee Chand, from competing at the world championships in London in August but it could have a significant impact on the Cas hearing later this month. It is bound to reopen the controversial and emotionally charged debate around the treatment of female athletes with hyperandrogenism, a medical condition characterised … Continue reading →

CLEVELAND--(BUSINESS WIRE)--Diasome Pharmaceuticals, Inc., an innovative life sciences technology company focused on the development of novel therapies for the treatment of diabetes and other metabolic conditions, announced the agreement today of new funding of up to $30 million led by Medicxi, a leading European life sciences venture capital firm. Diasome is the first investment from Medicxis recently announced Growth Fund I. Other investors in this round include the JDRF T1D Fund (Boston, MA), Black Beret Life Sciences, LLC (Houston, TX), and an investor group led by McDonald Partners, LLC (Cleveland, OH). Diasome's Hepatocyte Directed Vesicles (HDV) technology additive to commercial insulin therapies allows preferential delivery of insulin to the liver's hepatocytes. HDV-insulin is the most clinically advanced novel pre-meal insulin in the global insulin pipeline, and if approved would represent the first insulin therapy specifically designed to mimic the mealtime exposure of the liver to insulin. The investment by Medicxi, JDRF T1D Fund, Black Beret, and McDonald Partners represents a significant validation of Diasomes technology, and we will benefit from their track records of working with and advising successful drug development companies,said Robert Geho, CEO of Diasome. Medicxi founding partner Dr. Michele Ollier said, It has never been understood why … Continue reading →

PAO GROUP INC COM USD0.001 (OTCMKTS:PAOG) is a holding group for what was formerly known as New Wave Holdings. The company is going through a rebranding and in the process of opening up alternative medical centers where medical cannabis is legal. PAOG, formerly NWAV, is a publicly traded holdings company dedicated to the development and launch of PAO Group alternative medicine clinics focused on non-traditional patient care solutions. The realm of treatment solutions include cannabis, acupuncture, chiropractic, biofeedback, and other solutions depending upon patient needs. NWAV recently merged withPAO Group, Inc. (which will trade under PAOG), a physicians practice management company actively developing alternative medicine clinics focused on the proper use of cannabis for treatment of chronic and terminal patients. PAO GROUP INC COM USD0.001 (OTCMKTS:PAOG) has an expansion strategy in mind and it is working to methodically grow. On Jun 26, 2017, PAOG announced the launch of two new Corporate locations for its Alternative Medicine Centers of America. The new locations will open in Toledo and Dayton, Ohio. An in-house psychiatrist will help assist with properly diagnosing PTSD patients at the Dayton location. The Parma and Toledo locations will feature a full suite of therapeutic services as part of … Continue reading →

BBC News Swansea Uni trial to reduce breast cancer hot flushes - BBC News BBC News Scientists will investigate how behavioural therapy could help control difficult side effects. and more » Visit link: Swansea Uni trial to reduce breast cancer hot flushes - BBC News - BBC News … Continue reading →

Yeovil Hospital is to participate in a new clinical trial funded by the charity Breast Cancer Now to investigate the best way to deliver cognitive behavioural therapy (CBT) to reduce the impact of two major side-effects for women undergoing breast cancer treatment. Hot flushes and night sweats are common side effects of current breast cancer treatments such as chemotherapy and anti-hormone drugs. Experienced by up to 70 per cent of women receiving treatment, they can have a huge impact on their daily lives, often affecting employment, personal relationships and general quality of life, and sometimes leading to women not completing the full course of their treatment. Hormone replacement therapy (HRT), which is normally offered to women experiencing hot flushes as part of the menopause, unfortunately cannot be used by women with breast cancer as it can increase the risk of their disease returning. In addition, these side effects can often be more extreme and longer lasting in women who have had breast cancer than those experienced during natural menopause. It is therefore essential that scientists and clinicians find ways to help women undergoing breast cancer treatment reduce the impact of these side effects, to give them the best possible quality … Continue reading →